Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.

Abstract

BACKGROUND:

With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at one year is approximately 30% and justify extensive research of predictive biomarkers. If in metastatic disease, the follow-up of circulating tumor DNA (ctDNA) has been demonstrated, its interest in adjuvant setting remains to be precised, especially because of a lower detection rate. Further, the definition of a molecular response could prove useful to personalized treatment.

METHODS:

PERCIMEL is an open prospective multicentric study executed through collaboration of the Institut de Cancérologie de Lorraine (non-profit comprehensive cancer center) and 6 French university and community hospitals. A total of 165 patients with resected stage III and IV melanoma, eligible to adjuvant imunotherapy or anti-BRAF/MEK kinase inhibitors will be included. The primary endpoint is the presence of ctDNA, 2 to 3 weeks after surgery, defined as mutated ctDNA copy number calculated as the allelic fraction of a clonal mutation relative to total ctDNA. Secondary endpoints are recurrence-free survival, distant metastasis-free survival and specific survival. We will follow ctDNA along treatment, quantitatively through ctDNA mutated copy number variation, qualitatively through the presence of cfDNA and its clonal evolution. Relative and absolute variations of ctDNA during follow-up will be also analyzed. PERCIMEL study aims at provide scientific evidence that ctDNA quantitative and qualitative variations can be used to predict the recurrence of patients with melanoma treated with adjuvant immunotherapy or kinase inhibitors, thus defining the notion of molecular recurrence.

• Authors: Lionnel Geoffrois, Alexandre Harlé, Nassim Sahki, Aleksandra Sikanja, Florence Granel-Brocard, Alice Hervieu, Laurent Mortier, Géraldine Jeudy, Catherine Michel, Charlée Nardin, Cécile Huin-Schohn, Jean-Louis Merlin
• Journal: BMC cancer (BMC Cancer) Vol. 23 Issue 1 Pg. 554 (Jun 16 2023) ISSN: 1471-2407 [Electronic] England
• PMID: 37328818 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• Cell-Free Nucleic Acids
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins B-raf

Topics

• Humans
• Melanoma (genetics, therapy, pathology)
• Skin Neoplasms (drug therapy, genetics)
• Prospective Studies
• Cell-Free Nucleic Acids
• Follow-Up Studies
• DNA Copy Number Variations
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins B-raf (genetics)
• Mutation